Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
about
Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient RegistryAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisAntibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationDuration of intravenous antibiotic therapy in people with cystic fibrosisDuration of intravenous antibiotic therapy in people with cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisNeutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapyEarly detection of Pseudomonas aeruginosa--comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF)CD14 C-159T and early infection with Pseudomonas aeruginosa in children with cystic fibrosis.Treatments for preventing recurrence of infection withPseudomonas aeruginosain people with cystic fibrosisPseudomonas aeruginosa in premise plumbing of large buildingsBacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current statusTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisClinical applications of pulmonary delivery of antibioticsThe Evolution of Cystic Fibrosis CareColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyAnti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear NeutrophilsExhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosisAdvances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patientsChanges in cystic fibrosis airway microbial community associated with a severe decline in lung function.Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosisComparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosisExome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosisNonparametric estimation of the mean function for recurrent event data with missing event category.Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortiumRespiratory pathogens adopt a chronic lifestyle in response to bile.Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.Impact of multidrug-resistant organisms on patients considered for lung transplantation.Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation.Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyBronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosaOral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.Influenza-associated cystic fibrosis pulmonary exacerbations.Chest computed tomography predicts the frequency of pulmonary exacerbations in children with cystic fibrosis.Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis
P2860
Q22305306-DCCB9713-DB9A-49D2-BC7F-A960C08B7392Q24188054-C796FC96-4BE0-4225-B462-4796A43E5279Q24198135-ED72DA74-129F-4F08-9B18-78A1220B992BQ24202855-9518DC31-3169-4DDB-B0A1-E1E0740A4329Q24234667-AC2EBB6A-D412-48D5-B93E-DB32EAC61747Q24240388-C30D217C-27B3-4DB7-BF97-885B00038607Q24650612-7D5FE737-0E7A-49F2-83FD-70A6D0C7CD14Q24795985-FA87AEF2-C0F5-4FE3-BA79-5F0BF9A37AE1Q24815247-D5900271-6C89-4368-9658-1A3D52166FBAQ26470661-EF06BAEB-62CF-41C5-9BCB-659BF688F1CEQ26746248-48C0B3C3-A8B5-4446-ACB7-CA5E4A4F283AQ26799417-434F19E4-8AB6-49F8-B40F-BDF7B67E4ABCQ26829604-AA774DBD-3DCC-4214-8BAA-4BB3FA52EC89Q26996053-2BCC55A6-8683-4D74-8801-96ED0251D113Q26999299-3728F954-E81E-47FC-896A-6AD46D36EB31Q27014993-A7E619AA-F832-45AA-843B-6B7F38FF9E6BQ27322540-FCD8BC22-31AD-4466-9619-0573C2692A87Q28596799-DED20645-F1F7-48E3-9270-B98B9125585BQ28658389-DABF9BAE-5821-4A6E-9921-0C1176189647Q30388877-2647438F-4319-4C9F-AB7D-33492C000FD7Q30412485-81F36A75-4949-47A8-B236-48AF28F30665Q30413773-E46255AB-3E5A-4D8D-AC06-63DA6E3C350EQ30422695-F5F93A26-12C2-4EA6-BF63-A951C38CD2BAQ30452653-C550360F-34FF-4957-8157-B9249122667BQ30731623-ADFCF49B-CA0F-4A6D-8871-D7F2CC14BBB2Q30790275-2C060D34-0E7D-40DB-9C71-29667C59C1E9Q31008319-03AC2661-2535-47C1-B4AC-30AD9B7BF210Q31103147-C26ED967-80ED-48BD-8B6A-AA1D4E283D1CQ33474273-E9478C63-A5D8-47F3-8270-F8BC3EB4B4DAQ33576059-BC56AD17-BC09-4B57-B399-9852AF997CD0Q33592546-7726984D-C0D7-4EA3-9114-74365497DD69Q33654992-57EA57F3-DABA-4EC9-BB40-40F5D245C325Q33688123-07F1AC4E-6B1E-4E78-9092-EBA569060FDAQ33697276-218E64E6-836A-40F6-81E8-9D5BDBD2C7E8Q33701145-91A4D89C-CA54-4F26-AC16-801261B530A8Q33725822-97A0A297-7C5D-491B-94ED-7D240FF807D9Q33755342-739B18A7-D2E7-41F9-A285-57E1B4A67820Q33776832-456B3339-A38D-4E42-865C-0BE79D5FD4D5Q33783243-2660772E-9AC4-4B21-80B6-40E0E9839134Q33785116-F498525B-F068-402D-91E8-B88BE5BAC668
P2860
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Pseudomonas aeruginosa and oth ...... children with cystic fibrosis.
@en
Pseudomonas aeruginosa and oth ...... children with cystic fibrosis.
@nl
type
label
Pseudomonas aeruginosa and oth ...... children with cystic fibrosis.
@en
Pseudomonas aeruginosa and oth ...... children with cystic fibrosis.
@nl
prefLabel
Pseudomonas aeruginosa and oth ...... children with cystic fibrosis.
@en
Pseudomonas aeruginosa and oth ...... children with cystic fibrosis.
@nl
P2093
P2860
P356
P1476
Pseudomonas aeruginosa and oth ...... children with cystic fibrosis.
@en
P2093
Bonnie Ramsey
Julia Emerson
Margaret Rosenfeld
Ronald L Gibson
Sharon McNamara
P2860
P304
P356
10.1002/PPUL.10127
P577
2002-08-01T00:00:00Z